In the run up to the 2019 general election, the Indian government has prioritised healthcare delivery and promoting innovation and competitiveness in the country, including in the health and life sciences sector.
Section 3(d) of India’s patent law may be putting India at a competitive disadvantage. The data presented in this research note shows it is preventing Indian generic pharmaceutical companies from developing new formulations, compositions, and combinations of existing medicines, which they instead undertake and commercialise abroad.
The European Commission (EC) outlined its plans to introduce a manufacturing waiver for Supplementary Protection Certificates (SPCs). If adopted, it would open the door for generic manufacturers to export medicines outside the EU while the SPC is still in force.
Following growing concern about the sustainability of healthcare systems, in the summer of 2016 EU Health Ministers invited the European Commission (EC) of the EU to review pharmaceutical innovation incentives.
Replacing patents with prizes to spur drug development is the idea of the moment. But this so-called “delinkage” won’t deliver the innovation and low-cost medicines claimed by its supporters, writes Philip Stevens.
This WIPO Global Challenges Report describes the innovation process for vaccines. It explains how the restricted availability of vaccines is due to impediments at every stage of the process. Most of these obstacles are manageable, and intellectual property rights are associated with only some of them.